The FDA has approved Scenesse for the treatment of patients with erythropoietic protoporphyria, a rare genetic metabolic disorder in which patients experience severe biochemical reactions following light exposure.
The Food and Drug Administration (FDA) has approved Aklief Cream 0.005% (trifarotene; Galderma) for the topical treatment of acne vulgaris in patients 9 years of age and older.
The FDA has approved Jynneos (smallpox and monkeypox vaccine, live, non-replicating; Bavarian Nordic) for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk for these infections.
The treatment was evaluated in a head-to-head phase 3 trial.
The FDA has expanded the indication for Teflaro (ceftaroline fosamil; Allergan) to include treatment of acute bacterial skin and skin structure infections in pediatric patients.
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
Cuts are being proposed for 5 controlled substances based on estimates of diversion.
A greater proportion of patients with moderate to severe plaque psoriasis achieved complete skin clearance with ixekizumab when compared with guselkumab, according to results from a phase 4 head-to-head study.
The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients.
Duobrii (halobetasol propionate and tazarotene; Ortho Dermatologics) has been made available for the topical treatment of plaque psoriasis in adult patients.
